🇺🇸 FDA
Patent

US 10465004

Frizzled receptor antibodies for treatment of cancer

granted A61KA61K2039/505A61P

Quick answer

US patent 10465004 (Frizzled receptor antibodies for treatment of cancer) held by TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Grant date
Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61P, A61P35/00